Series E · Biotech
Pathos AI closes $237m Series E for AI-guided oncology development
Bristol Myers Squibb leads the financing at an approximately $3bn valuation.
Pathos AI announced the closing of a $237 million Series E on October 23, led by Bristol Myers Squibb at an approximately $3 billion post-money valuation. Existing investors also participated.
The New York drug developer will expand its Foundry AI platform and advance its oncology pipeline. A priority is moving JSKN016, a bispecific antibody-drug conjugate, toward registrational studies. Foundry combines clinical and biological evidence to help select assets and guide trial decisions.
Use of funds
Scale the Foundry AI platform
Advance clinical oncology pipeline including JSKN016
Funding history
Series E · This round$237M